Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cell Cycle ; 19(5): 601-609, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32079456

RESUMO

MAFG antisense 1 (MAFG-AS1) is recently identified as a novel lncRNA and serves as a tumor promoter in several types of human tumor. However, no prior study has been performed to evaluate the role of MAFG-AS1 in gastric cancer. In our study, we found MAFG-AS1 expression was increased in gastric cancer tissue samples compared with normal gastric mucosa tissue samples, and associated with poor overall survival in gastric cancer patients at The Cancer Genome Atlas database. Furthermore, we confirmed the clinical and prognostic significance of MAFG-AS1 in gastric cancer. We found gastric cancer tissues and cell lines had remarkably increased MAFG-AS1 expression in comparison to normal gastric mucosa tissues and normal human gastric epithelial cell line, and high MAFG-AS1 expression was positively associated with diffuse type, advanced clinical stage, extensive depth of invasion, more lymph node metastasis, and present distant metastasis in gastric cancer patients. Moreover, high MAFG-AS1 expression acted as one of the independent poor prognostic factors for overall survival in gastric cancer patients. The loss-of-function study showed knocking down MAFG-AS1 expression inhibited gastric cancer cell proliferation, migration and invasion in vitro. In conclusion, MAFG-AS1 is probable to be a valuable prognostic biomarker, and a novel potential target for gastric cancer.


Assuntos
Biomarcadores Tumorais/genética , Progressão da Doença , Regulação Neoplásica da Expressão Gênica , Fator de Transcrição MafG/genética , RNA Longo não Codificante/genética , Proteínas Repressoras/genética , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/genética , Linhagem Celular , Linhagem Celular Tumoral , Humanos , Estimativa de Kaplan-Meier , Prognóstico , Modelos de Riscos Proporcionais , Neoplasias Gástricas/patologia
2.
Nanomaterials (Basel) ; 7(8)2017 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-28788077

RESUMO

PbS colloidal quantum dots (CQDs) solar cells have already demonstrated very impressive advances in recent years due to the development of many different techniques to tailor the interface morphology and compactness in PbS CQDs thin film. Here, n-hexane, n-octane, n-heptane, isooctane and toluene or their hybrids are for the first time introduced as solvent for comparison of the dispersion of PbS CQDs. PbS CQDs solar cells with the configuration of PbS/TiO2 heterojunction are then fabricated by using different CQDs solution under ambient conditions. The performances of the PbS CQDs solar cells are found to be tuned by changing solvent and its content in the PbS CQDs solution. The best device could show a power conversion efficiency (PCE) of 7.64% under AM 1.5 G illumination at 100 mW cm-2 in a n-octane/isooctane (95%/5% v/v) hybrid solvent scheme, which shows a ~15% improvement compared to the control devices. These results offer important insight into the solvent engineering of high-performance PbS CQDs solar cells.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA